FEATURESPACE
16.8.2022 16:02:11 CEST | Business Wire | Press release
Featurespace and Vital4 have signed a global partnership to provide the financial services industry with AI driven Watchlist, PEPs, Sanctions and Adverse Media screening through Featurespace’s award winning ARIC Risk Hub. With this partnership, ARIC Risk Hub for AML is a one stop, end-to-end financial crime prevention solution for the customer.
Through a single API, ARIC Risk Hub for AML will leverage the watchlist data collected and curated by Vital4 to enhance the performance of Featurespace’s self learning models, ultimately improving accuracy and reducing false positives in flagged entities and transactions. Vital4’s automated AML/ KYC data tools analyze more than 6,000 global watchlists to help identify subjects involved in sanctions, terrorism, or corruption.
“Given the complementary technologies of Featurespace and Vital4, the industry now has access to behavioral analytics coupled with sentiment analysis to truly identify the financial criminals in real time.” Said Dave Excell, Featurespace Founder.
Vital4’s AI driven system examines 13 important criteria to provide the highest levels of name-matching, removing the ambiguity of legacy systems that rely on fuzzy name matching that can miss critical data points.
“As financial crime becomes increasingly complex to combat, crossing borders and moving in real-time, AML professionals need a complete risk hub to effectively monitor and report suspicious transactions and remain compliant.” Said Amy Barbieri, Co-Founder and President of Vital4. “The risk of non-compliance has huge reputational impact, making the business case clear for technologies that improve the accuracy for anti-financial crime efforts”.
Featurespace and Vital4 are two Atlanta based AI driven technology companies led by industry leading women. The two companies are unified around a shared commitment to enable banks and financial instutions with the best technology to fight financial crime and make the world a safer place to transact.
Primary industry benefits:
AI Driven Watchlist Screening :
- Machine learning to manage increasing volume and variety of transactions and entities to screen and monitor
- Monitoring over 6,300 Watchlists and Global Sanctions in 200+ countries and regions
- Propriety entity and name matching to provide more accurate search results and reduce false positives
- Proprietary 13-point name matching algorithm – better than traditional fuzzy name matching logic
- Natural Language Processing and Sentiment Analysis to truly identify Adverse Media articles AI-powered tagging of individuals or businesses in articles
- Watchlists updated real-time
- Risk-based call-out depending on business rule logic, analytics output
Customer Screening
- Screening at onboarding, change of details and ongoing trigger-based or scheduled monitoring
- Risk-based screening policies determine depth of search
- Watchlist flags available for analysts and immediate use within rules
Real-time Transaction Screening
- Real-time enabled sanctions screening of specified transaction types (i.e. cross-border, wires, ACH)
- Screening of counterparties
- Instant responses and action tags
- Reviewed in context of wider account activity a single, intuitive UI
Featurespace continues to partner with best in class technologies to provide holistic FRAML solutions for smart thinking financial institutions. Featurespace's partnership with Vital4 provides customers with a consolidated view and ability to manage financial crime risks across AML, fraud and sanctions within a single next generation risk management platform. Featurespace’s partnership with Callsign provides Enhanced Authentication and Device ID and security is provided by Accertify, and Ciphertrace provides crypto intelligence for transactional monitoring.
About Featurespace
Featurespace is the world leader in enterprise grade technology that prevents fraud and fights financial crime. With a mission to make the world a safer place to transact, Featurespace helps banks and financial institutions protect consumers, and reduce risk and operating costs by providing industry-leading machine learning, financial crime prevention solutions. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks and is the first to profile both genuine and fraudulent behavior to identify and catch criminal activity in real time. Both are patent pending technologies that are central to Featurespace’s award winning ARIC™ Risk Hub. Over 70 direct customers and 100,000 merchants and financial institutions have put their trust in Featurespace’s technology including HSBC, NatWest, TSYS, Worldpay, Marqeta, Contis, Danske Bank, Akbank, Edenred and Permanent TSB. Founded in 2008, and headquartered in Cambridge, UK Featurespace has a team of over 400, operating globally from seven locations.
About Vital4
Vital4 is an award-winning global technology company that provides critical data to organizations for regulatory compliance and to help mitigate third-party risk. Striving to make the world a safer place, Vital4 helps identify illicit actors in the fight against financial crime, terrorism, fraud, and corruption. Vital4 was founded with four fundamental concepts in mind: compliance, accuracy, global insight, and value. The powerful search platform, Vital4Search, was built with a “tech first” approach anchored by AI and Machine learning and is the world’s fastest and most accurate proprietary data search technology on the market today. Vital4Search solves enterprise compliance problems by eliminating slow update cycles, shallow source pools and reducing the human error risk of manual legacy processes. Vital4 provides data solutions to thousands of users in banking, gaming, identity, gig economy, GRC, legal, insurance and 4 of the top 5 largest background screening companies in the world put their trust in Vital4.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
